I-Mab is a holding company. Through its subsidiaries, Co. is primarily engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries. Co.'s drug pipeline includes: Felzartamab (TJ202), which is a monoclonal antibody directed against CD38; Eftansomatropin alfa (TJ101), which is a recombinant human growth hormone being developed as a therapy for growth hormone deficiency; Lemzoparlimab (TJC4), which is a CD47 monoclonal antibody discovered and developed internally by Co. for cancer immunotherapy; and Uliledlimab (TJD5), which is an inhibitory antibody against human CD73. The IMAB YTD return is shown above.
The YTD Return on the IMAB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether IMAB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMAB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|